FDA Commissioner promises action on REMS misuse

9 November 2017
biosimilars_samples_large

US Food and Drug Administration Commissioner Scott Gottlieb has announced new draft guidance for the pharmaceutical industry affecting Risk Evaluation and Mitigation Strategies (REMS) submissions.

Dr Gottlieb said the US FDA was exploring a “two-pronged approach” to reforming the scheme, which was set up in 2007, by law, to manage any known or potential risks associated with a drug or biological product.

A REMS submission from a pharmaceutical company is required if the FDA thinks it is necessary to ensure that the benefits of the product outweigh the risks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars